Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry?

  title={Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry?},
  author={Andrew A. Toole},
  journal={The Journal of Law and Economics},
  pages={81 - 104}
  • Andrew A. Toole
  • Published 1 February 2007
  • Medicine
  • The Journal of Law and Economics
This paper analyzes how pharmaceutical research and development (R&D) investment responds to publicly supported biomedical research performed mainly at universities and nonprofit institutions. New microlevel data on investment, by the U.S. National Institutes of Health, allow measures of public basic and clinical research in seven medical classes to be included in a distributed lag model explaining pharmaceutical R&D investment. Using a panel of medical classes observed over 18 years, the… 
The Impact of Public Basic Research on Industrial Innovation: Evidence from the Pharmaceutical Industry
While most economists believe that public scientific research fuels industry innovation and economic growth, systematic evidence supporting this relationship is surprisingly limited. In a recent
he impact of public basic research on industrial innovation : vidence from the pharmaceutical industry
While most economists believe that public scientific research fuels industry innovation and economic growth, systematic evidence supporting this relationship is surprisingly limited. In a recent
Public subsidies for R&D and public sector pharmaceutical innovation
ABSTRACT This paper investigates the relationship between public subsidies for research and development (R&D) and public sector drug development. For the analyses, a novel dataset based on the
The Effects of Investment and Research Expenditure on Chemical and Pharmaceutical Industries
Considering the economic performance as a target for companies in chemical and pharmaceutical sectors, the main aim of this paper is to assess the impact of investment and research expenditure on
What are the respective roles of the public and private sectors in pharmaceutical innovation?
Overall, it is found that direct government funding is more important in the development of "priority- review" drugs-sometimes described as the most innovative new drugs-than it is for "standard-review" drugs.
Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
While being less than private investment, public funding shows its significance in R&D investment in China and is likely to be invested into less developed provinces with abundant natural herbal resources.
Public R&D Investments and Private-Sector Patenting: Evidence from NIH Funding Rules
The impact of scientific grant funding at the National Institutes of Health on patenting by pharmaceutical and biotechnology firms is quantified and a method for flexibly linking specific grant expenditures to private-sector innovations is developed.
Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom
The implied historical returns from UK government and charity funded investment in medical research in the UK compare favourably with the rates of return achieved on investments in the rest of the UK economy and are greatly in excess of the 3.5 % real annual rate of return required by the UK government to public investments generally.
Public–private contribution to biopharmaceutical discoveries: a bibliometric analysis of biomedical research in UK
The majority of publications acknowledged public institutions, whereas, commercial organisations were likely to support those with privately affiliated authors, and the need to foster collaborative research and to set adequate incentives for shared risks and benefits from investments in knowledge creation was discussed.
Does targeted, disease-specific public research funding influence pharmaceutical innovation?
  • Margaret Blume-Kohout
  • Medicine
    Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management]
  • 2012
There exists little evidence to suggest that increasing targeted public research funding for any specific disease will result in increased development of drugs to treat that disease, and there is no evidence that increases in NIH extramural grant funding for research focused on specific diseases will increase the number of related treatments investigated in the more expensive, late-stage trials.


Public-Private Interaction and the Productivity of Pharmaceutical Research
We examine the impact of publicly funded biomedical research on the in-house research of the for-profit pharmaceutical industry. Qualitative analysis of the history of the discovery and development
This paper examines the relationship between basic and applied pharmaceutical research. The authors focus on three stages of RD publication in medical journals; and industry-funded applied R&D. They
Public and private sector contributions to the discovery and development of "impact" drugs.
An assessment of the relationship between the private and public sectors in drug discovery and development of 21 "impact" drugs found that any attempt to measure the relative contribution of the public and private sectors to the research and development (R&D) of therapeutically important drugs is flawed.
Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry*
This paper argues theoretically and shows empirically that pharmaceutical R&D spending increases with real drug prices, after holding constant other determinants of research and development (R&D).
Science and Innovation: The US Pharmaceutical Industry During the 1980s
This book, written by a professor of economics, focuses on economics, but none of the topics mentioned above is discussed in any depth.
The impact of regulation on pharmaceutical research expenditures: a dynamic approach.
The impact of federal regulation of drug quality on research spending by the pharmaceutical industry is estimated and differences in response are tested econometrically and prove to be empirically significant.
Racing or spilling? : the determinants of research productivity in ethical drug discovery
This paper presents the results of a study of the determinants of research productivity in the pharmaceutical industry. Using disaggregated, internalfirm data at the research program level from ten
Examining the link between price regulation and pharmaceutical R&D investment.
  • J. Vernon
  • Business, Economics
    Health economics
  • 2005
This paper examines the link between price regulation and pharmaceutical research and development (R&D) investment. I identify two mechanisms through which price regulation may exert an influence on
The impact of public R&D expenditure on business R&D
This document attempts to quantify the aggregate net effect of government funding on business R&D in 17 OECD Member countries over the past two decades. Grants, procurement, tax incentives and direct